An observational study in Coronavirus Infections, Gut Microbiome and Childhood ALL, sponsored by Hallym University Kangnam Sacred Heart Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 3 Months to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-19.
Sponsored by Hallym University Kangnam Sacred Heart Hospital · Observational
Among 13 studies in Coronavirus Infections with a site in Korea, Republic of — 5 open to participants now, 6 under way, 4 of them phase 3. Coronavirus Infections · Korea, Republic of.
Among the 13 studies in Coronavirus Infections with a site in Korea, Republic of, this one is one of 2 that started in 2022, is one of 3 observational ones, and was the 9th registered.
1,112 studies on the registry are indexed under Coronavirus Infections; 52 are open to participants now.
Browse Coronavirus Infections studies →5 of the 13 studies in Coronavirus Infections with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Pfizer · Sites in Korea, Republic of, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Korea, Republic of, United States, Argentina and 16 more countries
Ages 12+
AstraZeneca · Sites in Korea, Republic of, United States, Argentina and 36 more countries
Ages 18+
Ansun Biopharma, Inc. · Sites in Korea, Republic of, United States, Australia and 2 more countries
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 40 Coronavirus Infections studies recruiting now, 24 (60%) set no upper age limit and 9 (23%) stop at 75 or younger; 13 take children under 18; 20 take healthy volunteers.
This study: 3 Months to 15 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 5
First in 2015; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 308 across 387 observational studies indexed under Coronavirus Infections.
Median enrollment 327 across the 10 interventional studies, 737 across the 3 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 13 have an industry lead sponsor. The 10 most frequent:
Hallym University Kangnam Sacred Heart Hospital is the lead sponsor of 34 studies on the registry; 2 are open to participants now.
Hallym University Kangnam Sacred Heart Hospital has 1 study filed under Coronavirus Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in Coronavirus Infections with a site in Korea, Republic of that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Coronavirus Infections with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Although COVID-19 infects gastrointestinal tissues, little is known about the roles of gut commensal microbes in susceptibility to and severity of infection. The investigators will analyze the alterations in fecal microbiomes of patients with COVID-19 infection during hospitalization.
Those who were hospitalized because of the COVID 19 were enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pediatric patient infected by COVID 19
Diagnostic Test: 16S rRNA sequencing
Pediatric patient without infection of COVID 19
Diagnostic Test: 16S rRNA sequencing
Fecal microbiome analysis using 16S rRNA sequencing
The analysis of fecal microbiome of patient with COVID 19
The analysis of fecal microbiome of patient with COVID 19, using 16S rRNA sequencing
Time frame: through study completion, an average of 1 year
Started Apr 2022 (actual). Primary completion is estimated for Dec 2023, 20 months after the start.
Of 228 non-industry observational studies under Coronavirus Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 20 months is above that.
Counting every sponsor, half of 245 studies reached it within 14 months; a quarter within 5 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hallym University Kangnam Sacred Heart Hospital